 Amyotrophic Lateral Sclerosis
"Amyotrophic Lateral Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Descriptor ID |
D000690
|
| MeSH Number(s) |
C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050
|
| Concept/Terms |
Amyotrophic Lateral Sclerosis- Amyotrophic Lateral Sclerosis
- Sclerosis, Amyotrophic Lateral
- Charcot Disease
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Lou Gehrig Disease
- Lou Gehrig's Disease
- Lou-Gehrigs Disease
- Disease, Lou-Gehrigs
- ALS (Amyotrophic Lateral Sclerosis)
- Gehrig's Disease
- Gehrig Disease
- Gehrigs Disease
Amyotrophic Lateral Sclerosis, Guam Form- Amyotrophic Lateral Sclerosis, Guam Form
- Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam
- Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam
- Guam Form of Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1
- Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1
- Guam Disease
- Disease, Guam
|
Below are MeSH descriptors whose meaning is more general than "Amyotrophic Lateral Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Amyotrophic Lateral Sclerosis".
This graph shows the total number of publications written about "Amyotrophic Lateral Sclerosis" by people in this website by year, and whether "Amyotrophic Lateral Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 1998 | 2 | 0 | 2 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 3 | 0 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 0 | 4 | | 2015 | 3 | 0 | 3 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 2 | 5 | | 2018 | 2 | 1 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 8 | 1 | 9 | | 2021 | 10 | 0 | 10 | | 2022 | 2 | 0 | 2 | | 2023 | 3 | 0 | 3 | | 2024 | 2 | 1 | 3 | | 2025 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Amyotrophic Lateral Sclerosis" by people in Profiles.
-
Hullock K, O'Cathain A, Sampson F, Woodward J, Coates E, Stavroulakis T, White SM, White D, Norman P, McDermott C. Optimising Calorie Intake for People With Amyotrophic Lateral Sclerosis: A Process Evaluation of a Complex Behaviour Change Intervention. Health Expect. 2025 Oct; 28(5):e70417.
-
Matthews AM, Whiteley AM. UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential. Biochem Soc Trans. 2025 Aug 29; 53(4):823-833.
-
Peace A, White DA, Hackney G, Bradburn M, Norman P, White S, Al-Chalabi A, Baird W, Beever D, Cade J, Coates E, Cooper C, Ezaydi N, Halliday V, Maguire C, Shaw PJ, Stavroulakis H, Waterhouse S, Young TA, McDermott CJ. Randomised controlled trial with parallel process evaluation and health economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with amyotrophic lateral sclerosis: study protocol. BMJ Open. 2025 May 27; 15(5):e096098.
-
Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Young E, Chase M, Pothier L, Harkey B, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Connolly MR, Berry JD, D'Agostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Heitzman D, Ajroud-Driss S, Appel SH, Shroff S, Katz J, Felice K, Maragakis NJ, Simmons Z, Goutman SA, Olney N, Miller T, Fernandes JA, Ilieva H, Jawdat O, Weiss MD, Foster L, Vu T, Ladha S, Owegi MA, Newman DS, Arcila-Londono X, Jackson CE, Swenson A, Heiman-Patterson T, Caress J, Fee D, Peltier A, Lewis R, Rosenfeld J, Walk D, Johnson K, Elliott M, Kasarskis EJ, Rutkove S, McIlduff CE, Bedlack R, Elman L, Goyal NA, Rezania K, Twydell P, Benatar M, Glass J, Cohen JA, Jones V, Zilliox L, Wymer JP, Beydoun SR, Shah J, Pattee GL, Martinez-Thompson J, Nayar S, Granit V, Donohue M, Grossman K, Campbell DJ, Qureshi IA, Cudkowicz ME, Babu S. Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025 Apr; 82(4):333-343.
-
Paganoni S, Fournier CN, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Ajroud-Driss S, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Shefner JM, Hall M, Kittle G, Berry JD, Babu S, Andrews J, Dagostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Heiman-Patterson T, Caress JB, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Harvey B, Patel S, Mahoney P, Duda PW, Cudkowicz ME. Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2459058.
-
Mejzini R, Caruthers MH, Schafer B, Kostov O, Sudheendran K, Ciba M, Danielsen M, Wilton S, Akkari PA, Flynn LL. Allele-Selective Thiomorpholino Antisense Oligonucleotides as a Therapeutic Approach for Fused-in-Sarcoma Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2024 Aug 03; 25(15).
-
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol. 2024 Jul; 23(7):687-699.
-
Obara CJ, Nixon-Abell J, Moore AS, Riccio F, Hoffman DP, Shtengel G, Xu CS, Schaefer K, Pasolli HA, Masson JB, Hess HF, Calderon CP, Blackstone C, Lippincott-Schwartz J. Motion of VAPB molecules reveals ER-mitochondria contact site subdomains. Nature. 2024 Feb; 626(7997):169-176.
-
Martin Schaff C, Kurent JE, Kolodziejczak S, Milic M, Foster LA, Mehta AK. Neuroprognostication for Patients with Amyotrophic Lateral Sclerosis: An Updated, Evidence-Based Review. Semin Neurol. 2023 10; 43(5):776-790.
-
Milstead RA, Link CD, Xu Z, Hoeffer CA. TDP-43 knockdown in mouse model of ALS leads to dsRNA deposition, gliosis, and neurodegeneration in the spinal cord. Cereb Cortex. 2023 05 09; 33(10):5808-5816.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|